HeartBeam has announced a commercial partnership with preventive cardiology practice ClearCardio, marking the medical technology company's first commercial customer. The agreement, structured as a Letter of Intent, outlines subscription-based commercial terms and a collaborative deployment plan for integrating HeartBeam's synthesized 12-lead ECG technology into ClearCardio's cardiac prevention programs.
The partnership represents a strategic alignment between the two companies, with ClearCardio planning to make an investment in HeartBeam. The staged rollout will enable ClearCardio patients to capture clinical-grade ECG readings from home using HeartBeam's patented cable-free 3D ECG system for arrhythmia assessment. This technology received FDA clearance for arrhythmia assessment in December 2024 and for its 12-lead ECG synthesis software in December 2025.
HeartBeam's platform technology creates the first-ever cable-free device capable of collecting ECG signals in three dimensions from three non-coplanar directions and synthesizing those signals into a 12-lead ECG. The company holds over 20 issued patents related to this technology enablement. This partnership supports HeartBeam's broader growth strategy, including expansion into concierge care and preventive cardiology networks, continued development of its 12-lead ECG patch monitor, and advancement of its AI-driven cardiac care initiatives.
The importance of this partnership lies in its potential to transform cardiac care delivery by moving critical diagnostic capabilities outside traditional medical facilities. By integrating HeartBeam's technology into ClearCardio's preventive programs, patients gain access to portable devices that can deliver actionable heart intelligence wherever they are. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care without requiring in-person clinic visits.
For the healthcare industry, this partnership represents a significant step toward more accessible cardiac monitoring. The technology addresses a critical gap in remote patient monitoring by providing clinical-grade 12-lead ECG data that was previously only available in medical facilities. This could lead to earlier detection of cardiac issues, more personalized prevention programs, and reduced healthcare costs associated with emergency cardiac events.
The commercial implications extend beyond this initial partnership, as HeartBeam positions its technology for broader adoption in preventive cardiology networks. The company's news and updates are available in its newsroom at https://ibn.fm/BEAT. Forward-looking statements in the announcement are subject to risks and uncertainties, including those discussed in the company's SEC filings, with full terms of use and disclaimers available at http://IBN.fm/Disclaimer.
